GLP-1 receptor agonists like semaglutide and liraglutide have demonstrated effectiveness in helping individuals with obesity and HFpEF improve their weight and quality of life; therefore, they should become an integral part of our therapeutic approach for these patients. The gene discussed is GLP1R; the disease is Obesity.